> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Probe Leads to Charge Against Drug Importer
- URL: https://www.fdaweb.com/fda-probe-leads-to-charge-against-drug-importer/
- Published: 2016-09-26T12:00:00.000Z
- Updated: 2026-09-14T21:34:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5136913

After an FDA Office of Criminal Investigations probe, federal prosecutors have charged a Hoover, AL man with receiving and reselling misbranded male enhancement drugs from China that could cause serious side effects in men taking medications containing nitrates. **Nabil Chagri** has been charged with one count of receiving and selling or offering to sell a misbranded prescription drug called Zhen Gong Fu because it did not declare that it contained sildenafil citrate, the active ingredient in Pfizer’s Viagra.

The Zhen Gong Fu labeling not only failed to disclose that the drug contained sildenafil, it also falsely and misleadingly stated that Zhen Gong Fu “does not affect heart diseases \[sic\], hypertension or diabetes,” according to a government [release](https://www.justice.gov/usao-ndal/pr/hoover-man-charged-marketing-misbranded-male-enhancement-drugs-china?ref=fdaweb.com). The mislabeled drugs were mailed to Chagri from China at various addresses in Alabama, it says. “Between 3/2015 and 3/2016, FDA detained multiple packages containing the drugs in route from China to Chagri and issued eight import detention notices against him.”